Our study not only suggests that there is synergistic anti-cancer benefits when docetaxel and anti-VEGFR3 therapy are administered together, but also underscores the benefit of anti-VEGFR3 to counteract docetaxel-induced lymphatic changes which could contribute to longer term treatment-associated issues and recurrence. The gene discussed is FLT4; the disease is cancer.